Treatment of Hepatocellular Carcinoma With Radiofrequency Ablation (RFA) Associated With Postoperative TACE

Treatment of Hepatocellular Carcinoma With Radiofrequency Ablation Associated With Postoperative Transhepatic Arterial Chemoembolization--a Prospective Randomized Clinical Trial

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00730860

Enrollment

140

Registered

2008-08-08

Start date

2009-12-31

Completion date

2018-06-30

Last updated

2017-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer of Liver

Keywords

radiofrequency ablation, Cancer of Liver, postoperative, transhepatic arterial chemoembolization, prospective

Brief summary

A RCT was conducted to elucidate whether the treatment outcome of HCC could be improved by RFA associated with postoperative TACE.

Detailed description

A randomized study was conducted to elucidate whether the outcome of hepatocellular carcinoma could be improved by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization.

Interventions

PROCEDUREradiofrequency ablation associated with TACE

treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization

PROCEDUREradiofrequency ablation only

treatment of hepatocellular carcinoma by radiofrequency ablation only

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* patients with hepatocellular,confirmed by pathological examination * patients with a live function test showed Child A or B * Indocyanine green test showed less than 30％ after 15min,and the patients showed a tolerance of RFA and TACE * Tumor stage is early period(according to Milan Standard),that is,the diameter of single node should be less than 5cm；the node of tumor should be less than 3 and the diameter less than 3cm. * without metastasis in lymphnode or other organs * written consent inform assigned

Exclusion criteria

* preoperative examination showed malignant thrombosis in the first class branch of portal vein or hepatic vein or vena cava * metastatic cancer of liver * patients with a poor tolerance of RFA and TACE * patients received other therapies.

Design outcomes

Primary

Measure	Time frame
disease free survival	3 years

Secondary

Measure	Time frame
overall survival	3 years

Countries

China

Contacts

Primary ContactFeng Xiaobin, M.D

fengxiaobin200708@yahoo.com.cn+86-23-68765297

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026